← Leaderboards
Alison Anne McCormick
New York Medical College
$2,896,419
Attributed
$4,864,753
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $868.2K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,864,753 · 6
By mechanism
R01$3,229,833 · 1
R21$1,490,220 · 4
R03$144,700 · 1
Top collaborators
- Eric A Weaver5 shared
- Paul Michael Arnaboldi3 shared
Most similar at New York Medical College
Same institution · by research overlap
- Paul Michael Arnaboldi$5,503,528
Others in their field
Top investigators on “Antigens”
- Barton F Haynes · Duke University$488,918,563
- Lawrence Corey · Fred Hutchinson Cancer Center$325,880,100
- Dennis R. Burton · Scripps Research Institute$291,395,948
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$245,204,950
- Jeffrey P Krischer · University Of South Florida$208,289,343
- Dan H. Barouch · Fred Hutchinson Cancer Center$124,506,327
Research focus
AntigensSurfaceVaccinesImmunogenicityImmunityVaccinationTobacco Mosaic VirusImmuneProteinsImmune ResponsePathogenVirusSubunit VaccinesBaseCharacteristicsPublic HealthPlantsImmunizationCellular ImmunityDesignHumoral ImmunitiesMouse ModelAntibodiesFuture
Grant awards (14)
Tobacco Mosaic Virus as a mucosal delivery platform for an intranasal vaccine against Pseudomonas aeruginosa$261,846
R21 · FY2025 · AI
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens$653,985
R01 · FY2024 · AI
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens$661,752
R01 · FY2023 · AI
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection$195,854
R21 · FY2023 · AI
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens$619,095
R01 · FY2022 · AI
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection$249,135
R21 · FY2022 · AI
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens$633,642
R01 · FY2021 · AI
Rapid Manufacturing of a Universal Flu Vaccine Using TMV-conjugated Centralized Antigens$661,359
R01 · FY2020 · AI
Virus-DNA-Virus hybrid vaccines for the prevention of Influenza$234,375
R21 · FY2018 · AI · contact PI
Virus-DNA-Virus hybrid vaccines for the prevention of Influenza$178,750
R21 · FY2017 · AI · contact PI
Adaptation of a Novel RNA virus for vaccine use$72,350
R03 · FY2013 · AI · contact PI
Adaptation of a Novel RNA virus for vaccine use$72,350
R03 · FY2012 · AI · contact PI
Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery$201,960
R21 · FY2010 · CA · contact PI
Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery$168,300
R21 · FY2009 · CA · contact PI